CA
ESPR icon

Clearstead Advisors’s Esperion Therapeutics ESPR Stock Holding History

Clearstead Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,034
Closed -$2.74K – 2904
2025
Q3 		$2.74K Buy
1,034
+656
+174% +$1.27K ﹤0.01% 2357
2025
Q2 		$373 Sell
378
-2,122
-85% -$2.13K ﹤0.01% 2518
2025
Q1 		$3.6K Hold
2,500
– – ﹤0.01% 1799
2024
Q4 		$5.5K Hold
2,500
– – ﹤0.01% 1701
2024
Q3 		$4.13K Hold
2,500
– – ﹤0.01% 1742
2024
Q2 		$5.55K Hold
2,500
– – ﹤0.01% 1669
2024
Q1 		$5.58K Buy
+2,500
New +$6.08K ﹤0.01% 1161

Other funds holding ESPR

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $2.17B AUM 169.27% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return